FDA-in Chikungunya vaccine pawm fel ta

US Food and Drug Administration chuan ’emerging global health threat’ tia sawi Chikungunya vaccine hmasa ber chu a pawm fel ta.
He natna hi thosi putdarh theih niin khawsik sang tak leh ruh chuktuah natak thlen thei niin a bik takin naupang ten an tuar na hle thei a ni.
FDA-in remtihna pea a pawm tak avang hian khawvel huapin vaccine pek chhuah chu chak zawka kalpui theih a nih beisei a ni.
Kumin hian Chikungunya case 440,000 vel awmin nunna chan phah 350 vel September thla thleng khan an awm tawh anga ngaih a ni a.
Chikunguya enkawlna tur damdawi hi a la awm ngai lo va. A bik takin South America leh South Asia te chu kumin hian vei tamna ber hmun a ni bawk.
Vaccine siam thar hi Ixchiq tih niin kum 18 chin chunglam te tan chauh a ni tiin FDA chuan a sawi a. A siamtute hi Europe-a Valneva te niin tum khata pek tur a ni bawk.
“Chikunguya virus hian natna hrehawm tak leh hun rei tak hasratna a thlen thei a, a bik takin kum upa zual lam leh natna benvawn nei te tan a hlauhawm zual” tiin senior FDA official peter Marks chuan a sawi.
Kum 2008 hnu atang khan chikungunya case maktaduai 5 chuang awm tawhin he natna hian thak nasa tak te, lu na leh tha na te pawh a siam thei a. Ruh chuktuahna phei chu an kai hnu leh dam hnuah pawh thla tam tak a kum a kum te pawh a awh zui thei tih a ni bawk.
Tropical leh subtropical regions of Africa, Southeast Asia, Americas hmun thenkhatte chu thosi he natna pudarh theite tamna a nih avangin a hluar zual a ni.
“Chikungunya hi geographical area dang dangah pawh darh thei a nih avangin khawvel tuam thei a ni,” tiin FDA chuan a sawi bawk.
European Centre for Disease Prevention and Control data chuan kumin hian Brazil-ah Chikungunya vei ngah berin 218,613 an awm tiin a sawi a.
India ramah pawh kai 93,000 chhinchhiah niin kum 2016 khan capital Delhi-ah chuan a leng darh vak tawh bawk.